DIR Return Create A Forum - Home
---------------------------------------------------------
Camelot Fantasies
HTML https://castleknights.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: Stocks Universe
*****************************************************
#Post#: 64940--------------------------------------------------
MBRX
DIR By: Clay Death
Date: July 18, 2017, 6:03 pm
---------------------------------------------------------
HTML https://finance.yahoo.com/quote/MBRX?p=MBRX
HTML https://finance.yahoo.com/quote/MBRX?p=MBRX
Moleculin Signs Agreement with MD Anderson Cancer Center for
Leukemia Drug, Annamycin
MarketwiredJuly 18, 2017
Comment
HOUSTON, TX--(Marketwired - July 18, 2017) - Moleculin Biotech,
Inc., (MBRX) ("Moleculin" or the "Company"), a preclinical
pharmaceutical company focused on the development of anti-cancer
drug candidates, some of which are based on license agreements
with The University of Texas System on behalf of the M.D.
Anderson Cancer Center, today announced it has signed a new
technology license agreement with MD Anderson Cancer Center
based on new patent applications it intends to file relating to
its drug Annamycin for the treatment of relapsed or refractory
acute myeloid leukemia (AML).
"In anticipation of beginning our planned clinical trials for
Annamycin," commented Walter Klemp, CEO of Moleculin, "one of
our priorities has been to ensure the best possible protection
for our intellectual property. Some key patent applications had
yet to be filed and signing a new license agreement with MD
Anderson clears the way for those patents."
Mr. Klemp continued: "we have benefitted greatly from our
collaboration with MD Anderson, and this license helps ensure
that collaboration continues."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a preclinical stage pharmaceutical
company focused on the development of anti-cancer drug
candidates, some of which are based on discoveries made at M.D.
Anderson Cancer Center. Our lead product candidate is Annamycin,
an anthracycline being studied for the treatment of relapsed or
refractory acute myeloid leukemia, more commonly referred to as
AML. We also have two preclinical small molecule portfolios, one
of which is focused on the modulation of hard-to-target tumor
cell signaling mechanisms and the recruitment of the patient's
own immune system. The other portfolio targets the metabolism of
tumors.
For more information about the Company, please visit
HTML http://www.moleculin.com
.
#Post#: 64941--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: July 18, 2017, 6:05 pm
---------------------------------------------------------
HTML https://finance.yahoo.com/news/reminder-moleculin-announces-conference-call-113000523.html
HTML https://finance.yahoo.com/news/moleculin-appoints-lead-european-principal-113000788.html
HTML https://finance.yahoo.com/news/corporate-news-blog-moleculin-biotech-121500227.html
#Post#: 65738--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: July 26, 2017, 11:57 am
---------------------------------------------------------
HTML https://finance.yahoo.com/news/moleculins-drug-treatment-glioblastoma-nears-113000315.html
#Post#: 66390--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: July 31, 2017, 8:46 am
---------------------------------------------------------
$MBRX:
Institutional holders:
Moleculin Biotech Inc, Inst Holders, 2Q 2017 (MBRX)
4:15 am ET July 20, 2017 (Dow Jones) Print
The following table shows the largest shareholders in MOLECULIN
BIOTECH INC COM (MBRX) for the quarter ended June 30, 2017,
listed by holding size. The list represents up to 50 of the
largest holders in the company.
Institution Shares Shares % Last
Held Changed Held Report
The Vanguard Group Inc. 264,160 246,202 1.488 03/31
KCG Americas LLC 233,994 233,994 1.318 03/31
Sabby Capital LLC 100,000 100,000 0.563 03/31
Sterling Capital Management LL 40,000 20,000 0.225 03/31
Bank of America NA (Private B 25,000 0 0.141 03/31
Two Sigma Securities LLC 24,160 24,160 0.136 03/31
BlackRock Fund Advisors 17,868 0 0.101 03/31
Goldman Sachs & Co. LLC (Priva 17,509 17,509 0.099 03/31
Citadel Advisors LLC 17,304 17,304 0.097 03/31
Northern Trust Investments In 11,155 11,155 0.063 03/31
Morgan Stanley & Co. LLC 10,096 10,096 0.057 03/31
Wedbush Securities Inc. (Inve 10,000 10,000 0.056 03/31
UBS Securities LLC 4,537 2,415 0.026 03/31
Tower Research Capital LLC 3,100 2,900 0.017 03/31
Acrospire Investment Managemen 2,472 2,472 0.014 03/31
UBS Financial Services Inc. 2,000 2,000 0.011 03/31
Advocacy Wealth Management LLC 1,000 0 0.006 03/31
Morgan Stanley Smith Barney LL 700 0 0.004 03/31
NEXT Financial Group Inc. 500 500 0.003 06/30
WFG Advisors LP 400 0 0.002 03/31
Citigroup Global Markets Inc. 0 (7,500) 0.000 03/31
#Post#: 66391--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: July 31, 2017, 8:47 am
---------------------------------------------------------
--- Quote from: Clay Death link ---
>
> $MBRX:
>
>
> Institutional holders:
>
>
>
> Moleculin Biotech Inc, Inst Holders, 2Q 2017 (MBRX)
> 4:15 am ET July 20, 2017 (Dow Jones) Print
>
> The following table shows the largest shareholders in
MOLECULIN BIOTECH INC COM (MBRX) for the quarter ended June 30,
2017, listed by holding size. The list represents up to 50 of
the largest holders in the company.
>
>
>
> Institution Shares Shares % Last
> Held Changed Held Report
>
>
>
>
>
>
>
> The Vanguard Group Inc. 264,160 246,202 1.488 03/31
> KCG Americas LLC 233,994 233,994 1.318 03/31
> Sabby Capital LLC 100,000 100,000 0.563 03/31
> Sterling Capital Management LL 40,000 20,000 0.225 03/31
> Bank of America NA (Private B 25,000 0 0.141 03/31
> Two Sigma Securities LLC 24,160 24,160 0.136 03/31
> BlackRock Fund Advisors 17,868 0 0.101 03/31
> Goldman Sachs & Co. LLC (Priva 17,509 17,509 0.099 03/31
> Citadel Advisors LLC 17,304 17,304 0.097 03/31
> Northern Trust Investments In 11,155 11,155 0.063 03/31
> Morgan Stanley & Co. LLC 10,096 10,096 0.057 03/31
> Wedbush Securities Inc. (Inve 10,000 10,000 0.056 03/31
> UBS Securities LLC 4,537 2,415 0.026 03/31
> Tower Research Capital LLC 3,100 2,900 0.017 03/31
> Acrospire Investment Managemen 2,472 2,472 0.014 03/31
> UBS Financial Services Inc. 2,000 2,000 0.011 03/31
> Advocacy Wealth Management LLC 1,000 0 0.006 03/31
> Morgan Stanley Smith Barney LL 700 0 0.004 03/31
> NEXT Financial Group Inc. 500 500 0.003 06/30
> WFG Advisors LP 400 0 0.002 03/31
> Citigroup Global Markets Inc. 0 (7,500) 0.000 03/31
>
>
>
--- End Quote ---
this says it all.
MBRX is the real deal.
#Post#: 66572--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: August 3, 2017, 8:19 am
---------------------------------------------------------
Moleculin Biotech, Inc. (NASDAQ: MBRX), a preclinical
pharmaceutical company focused on the development of anti-cancer
drug candidates, some of which are based on license agreements
with The University of Texas System on behalf of the MD Anderson
Cancer Center, today announced it has selected Bioscience SA
('Bioscience'), a Polish contract research organization ('CRO')
to begin identifying and preparing clinical testing sites in
Poland for Annamycin, its drug candidate for the treatment of
relapsed or refractory acute myeloid leukemia (AML). The Company
announced on June 15th, an expansion of its agreement with
Theradex Systems, Inc. to include oversight of clinical trial
activity in Poland and the appointment of a Lead European
Principal Investigator on July 6, 2017. Read this and more news
for Moleculin Biotech at:
HTML http://www.marketnewsupdates.com/news/mbrx.html.
"Engaging Bioscience gives us experienced boots on the ground in
Poland," commented Walter Klemp, CEO of Moleculin, "which we
believe is critical, not only for ensuring tight coordination
between the US and Polish sites in our upcoming Annamycin
clinical trial (which would commence only if our IND for
Annamycin is permitted), but also to ensure we have the full
benefit of local knowledge regarding site performance and
regulatory compliance."
Mr. Klemp continued, "one of the biggest challenges for most
clinical trials is recruiting the right patients on a timely
basis. We believe adding Polish sites to our planned trial
introduces a significant population of qualified patients, and
selecting Bioscience helps ensure we reach those patients
effectively and efficiently."
#Post#: 66587--------------------------------------------------
Re: MBRX
DIR By: Swish
Date: August 3, 2017, 9:17 pm
---------------------------------------------------------
This looks very good.
The price doubled in a month, a nice gradual increase.
Today it went up 5%.
I've been looking for something lately to add that's solid, this
may be the one.
Good find CD.
#Post#: 66589--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: August 3, 2017, 9:20 pm
---------------------------------------------------------
--- Quote from: Swish link ---
>
> This looks very good.
>
> The price doubled in a month, a nice gradual increase.
>
> Today it went up 5%.
>
> I've been looking for something lately to add that's solid,
this may be the one.
>
> Good find CD.
>
--- End Quote ---
it is up another 13 cents after hours.
I think tomorrow it crosses over to $3 and more for good.
we will just have to see how it plays out.
you know all these stocks entail risk.
#Post#: 67055--------------------------------------------------
Re: MBRX
DIR By: Clay Death
Date: August 16, 2017, 8:10 am
---------------------------------------------------------
Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate
Developments and Clinical Trial Progress
8:30 am ET August 16, 2017
MarketNewsUpdates.com News Commentary
This month's latest FDA Approval advancements, anti-cancer drug
candidate developments and Clinical studies momentum across the
biotech and pharma sector continues to accelerate as headlines
surrounding the active biotechnology industry advances forward
resulting in new levels in the markets. The iShares Nasdaq
Biotechnology Index has realized a healthy gain of around 15% so
far this year from leaders in the industry including: Moleculin
Biotech, Inc. (NASDAQ: MBRX), Teva Pharmaceutical Industries
Limited (NYSE: TEVA), Endo International plc (NASDAQ: ENDP),
Gilead Sciences Inc. (NASDAQ: GILD) and Microbot Medical Inc.
(NASDAQ: MBOT)
Moleculin Biotech, Inc. (NASDAQ: MBRX), a preclinical
pharmaceutical company focused on the development of anti-cancer
drug candidates, some of which are based on license agreements
with The University of Texas System on behalf of the MD Anderson
Cancer Center, today announced it has acquired WP1122 active
drug compound it plans to study for the treatment of brain
tumors. Read this and more news for Moleculin Biotech at
HTML http://www.marketnewsupdates.com/news/mbrx.html
Walter Klemp, CEO of Moleculin commented: "There has been a lot
of excitement recently surrounding the WP1122 technology and its
potential to become a new approach for treating brain tumors. We
are pleased that we have now secured exclusive access to a
significant quantity of GMP synthesized WP1122 drug substance
from our sublicense partner in Poland."
"Access to this product allows us to accelerate pre-clinical
toxicology and analytical testing of WP1122," Mr. Klemp
continued, "which enables preparation of an Investigational New
Drug application so we can begin proof of concept clinical
trials. Research at MD Anderson using live human brain tumors
transplanted into mice has shown that WP1122 has the potential
to outperform the current standard of care treatment for
glioblastoma, one of the most pervasive forms of brain tumors.
We are eager to get this drug into human testing to determine if
we have something that could make a real difference for
patients."
In other biotech developments and market performance of note:
Teva Pharmaceutical Industries Limited (NYSE: TEVA) came to a
close up 4.72% on Tuesday at $17.97 trading over 22.6 million
shares by the market close and was down very slightly in
afterhours trading. The company recently announced that the U.S.
Food and Drug Administration (FDA) has approved QVAR(R)
RediHaler(TM) (beclomethasone dipropionate HFA) inhalation
aerosol, a breath-actuated inhaler for the maintenance treatment
of asthma as a prophylactic therapy in patients four years of
age and older. QVAR(R) RediHaler(TM) is not indicated for the
relief of acute bronchospasm. The product is expected to become
commercially available in both 40mcg and 80mcg strengths to
patients by prescription during the first quarter of 2018.
Endo International plc (NASDAQ: ENDP) closed up over 6% on
Tuesday at $8.14 with over 9.9 million shares traded on the day.
The company recently announced second-quarter 2017 financial
results. Total revenues decreased by 5 percent to $876 million
in second-quarter 2017 compared to the same period in 2016
primarily due to generic competition adversely impacting the
Branded Established Products portfolio. GAAP net loss from
continuing operations in second-quarter 2017 was $696 million
compared to GAAP net income from continuing operations of $390
million during the same period in 2016. This decrease was
primarily attributable to charges associated with the Company's
manufacturing network restructuring; after-tax impairment
charges associated with market and competitive factors impacting
certain products' revenues, the pending Somar divestiture and
the market removal of OPANA(R) ER; and second-quarter 2016
recognition of certain net tax benefits. GAAP net loss per share
from continuing operations for the second-quarter 2017 was
$3.12, compared to diluted GAAP EPS from continuing operations
of $1.75 in second-quarter 2016. Read more here:
HTML https://finance.yahoo.com/news/endo-reports-second-quarter-2017-103000822.html<br
/>
Gilead Sciences Inc. (NASDAQ: GILD) closed up slightly on
Tuesday with over 5.1 million shares traded by the market close.
The company recently announced that the U.S. Food and Drug
Administration (FDA) has granted priority review for the
company's New Drug Application (NDA) for an investigational,
fixed-dose combination of bictegravir (50mg) (BIC), a novel
investigational integrase strand transfer inhibitor (INSTI), and
emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a
dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead
filed the NDA for BIC/FTC/TAF with a Priority Review voucher on
June 12, 2017, and FDA has set a target action date under the
Prescription Drug User Fee Act (PDUFA) of February 12, 2018.
Microbot Medical Inc. (NASDAQ: MBOT) closed up over 12% on
Tuesday with over 1.3 million shares traded by the market close.
The company recently announced financial and operational results
for the quarter and six months ended June 30, 2017, as well as
provided an update on progress towards key strategic
initiatives. "As major healthcare companies are seeking to
establish capabilities in the medical robotic space, our team is
leveraging Microbot's already existing and unique core
capabilities and is making meaningful progress with our
transformational technological robotic platforms," commented
Harel Gadot, CEO, President and Chairman. Read more here:
HTML https://finance.yahoo.com/news/microbot-medical-inc-reports-second-200100412.html<br
/>
*****************************************************
Page 1 of 1